Oncotelic Therapeutics (OTLC) Cash & Equivalents (2010 - 2026)
Oncotelic Therapeutics (OTLC) posted Cash & Equivalents of $206,014 for Q2 2026, up 90.7% from $108,022 a year earlier.
Powered by 
Analysis
Oncotelic Therapeutics (OTLC) Cash & Equivalents (2010 - 2026) Analysis & Trends
At the end of FY2025, Oncotelic Therapeutics' Cash & Equivalents came in at $108,857, up 2.6% from FY2024.
- Annual Cash & Equivalents shows a five-year compound annual growth rate of -26.1% (FY2020 to FY2025).
- In prior years, Oncotelic Therapeutics' Cash & Equivalents was $106,128 in FY2024 (-44.3%), $190,405 in FY2023 (-27.2%), $261,452 in FY2022 (-55.6%) and $588,769 in FY2021 (+19.2%).
- Quarterly Cash & Equivalents has run from a low of $92,216 in Q2 2024 to a high of $588,769 in Q4 2021 over five years.
- On a year-over-year basis, Cash & Equivalents increased in four of the last seven quarters, with growth averaging 18.0%.
- The strongest year-over-year quarter for Cash & Equivalents in the past five years was Q3 2022, with growth of 179.2%; the weakest was Q3 2021, with a decline of 92.9%.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,109.83 Bn | 1,078.42 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 610.61 Bn | 529.14 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 500.66 Bn | 473.77 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 354.64 Bn | 309.02 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 291.14 Bn | 255.13 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 254.18 Bn | 227.87 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 229.46 Bn | 184.86 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 190.33 Bn | 164.53 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 167.92 Bn | 114.57 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Oncotelic Therapeutics | 8.28 Mn | 7.42 Mn | - | 206,014.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 206,014.00 |
| Dec 31, 2025 | 108,857.00 |
| Sep 30, 2025 | 429,000.00 |
| Jun 30, 2025 | 108,022.00 |
| Mar 31, 2025 | 99,173.00 |
| Dec 31, 2024 | 106,128.00 |
| Sep 30, 2024 | 169,018.00 |
| Jun 30, 2024 | 92,216.00 |
| Mar 31, 2024 | 208,989.00 |
| Dec 31, 2023 | 190,405.00 |
| Sep 30, 2023 | 288,022.00 |
| Jun 30, 2023 | 201,872.00 |
| Mar 31, 2023 | 210,435.00 |
| Dec 31, 2022 | 261,452.00 |
| Sep 30, 2022 | 273,882.00 |
| Jun 30, 2022 | 419,772.00 |
| Mar 31, 2022 | 117,906.00 |
| Dec 31, 2021 | 588,769.00 |
| Sep 30, 2021 | 98,081.00 |
| Jun 30, 2021 | 481,285.00 |
API Access
Oncotelic Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=OTLC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "OTLC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=OTLC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();